Author

M. T. Howard

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Organism:E. coli· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:whole-exome sequencing· 1

Frequent Co-Authors

A. A. Mangaonkar· 1 shared A. Buradkar· 1 shared A. J. Lewis· 1 shared A. Tran· 1 shared A. Vedder· 1 shared A. Yurchenko· 1 shared B. A. Fleming· 1 shared B. Alver· 1 shared

Activity by Year

2019-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. A. Mangaonkar

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Balanced Input from the tRNA Prenyltransferase MiaA Controls the Stress Resistance and Virulence Potential of Extraintestinal Pathogenic Escherichia coli

M. G. Blango, B. A. Fleming, W. M. Kincannon, A. Tran, A. J. Lewis, C. W. Russell, Q. Zhou, L. M. Baird, J. R. Brannon, C. J. Beebout, V. Bandarian, M. Hadjifraniskou, M. T. Howard, M. A. Mulvey

This study shows that MiaA, but not MiaB, is critical for the fitness and virulence of ExPEC, and that stress can alter MiaA expression to affect translation and proteome composition.

bioRxiv · Feb 2, 2021 · PreprintMicrobiology

RAS mutations drive proliferative chronic myelomonocytic leukemia via activation of a novel KMT2A-PLK1 axis

R. M. Carr, D. Vorobyev, T. Lasho, D. L. Marks, E. J. Tolosa, A. Vedder, L. Almada, A. Yurchenko, I. Padioleau, B. Alver, G. Coltro, M. Binder, S. L. Safgren, I. Horn, X. You, , M. M. Patnaik

This study identifies RAS mutations as drivers of proliferative CMML through a novel KMT2A-PLK1 axis, showing PLK1 inhibition can improve disease outcomes in patient-derived xenografts.

bioRxiv · Dec 23, 2019 · PreprintCancer Biology